THE 30STARTUPS OF KANSAI

JiMED is a Japan-based academic startup developing a fully implantable wireless Brain-Computer Interface (BCI) system based on research from Osaka University. Our technology captures brain signals from the cortical surface and decodes the user’s intended movements to control external devices. We are initially developing the system as a medical device for patients with severe neurological disorders who have lost the ability to communicate or move voluntarily. By combining implantable hardware, wireless technology, and AI-based brain-signal decoding, JiMED aims to translate advanced neuroscience into practical solutions that can restore human function and independence.

Patients with severe neurological diseases such as ALS may gradually lose the ability to speak, move, or communicate, even while remaining fully conscious. Existing assistive technologies often depend on residual muscle or eye movement and may become difficult to use as the disease progresses. JiMED’s implantable BCI is designed to enable patients to control external devices directly through brain signals, without relying on peripheral motor function. We initially aim to restore reliable communication, and in the future, to support broader activities such as computer operation and control of assistive devices, helping patients maintain independence, dignity, and social participation.

JiMED’s technology is distinguished by its fully implantable and wireless architecture combined with cortical-surface brain signal recording. Unlike intracortical BCIs that penetrate brain tissue, our system uses ECoG electrodes placed on the brain surface, aiming to achieve a balance between high-quality neural signals and reduced invasiveness. The system integrates multichannel brain-signal acquisition, wireless power and communication, and AI-based decoding in a compact implantable platform. JiMED also has access to core intellectual property originating from Osaka University and is building on more than a decade of academic research and engineering development in implantable BCI technology.

JiMED’s initial goal is to commercialize an implantable BCI for patients with severe communication impairment, beginning with ALS. Beyond communication, we plan to expand the platform to enable more advanced control of computers, mobility devices, robotic systems, and other assistive technologies. We also envision creating a high-quality intracranial brain-signal data platform that can contribute to the development of new therapies, digital biomarkers, and next-generation neurotechnology. Through global clinical development and partnerships with healthcare, technology, and medical device companies, JiMED aims to establish a scalable BCI platform that connects brain signals with real-world applications.